Demographic and clinical characteristics of the nested case–control population derived from the time-dependent sampling
| Cases | Controls | |
|---|---|---|
| N | 778 | 3083 |
| Demographics | ||
| Age (median—years) | 76 | 76 |
| Gender (% male) | 59.4 | 59.4 |
| Revascularisation procedures during the index admission | ||
| PCI (N; %) | 284; 36.5 | 1482; 48.0 |
| Bypass (N; %) | 6; 0.8 | 75; 2.4 |
| Comorbidities (index admissions and 9 years before) | ||
| Malignant neoplasm (N; %) | 96; 12.3 | 309; 10.0 |
| Diabetes (N; %) | 248; 31.9 | 488; 15.8 |
| Disorders of lipid metabolism/obesity (N; %) | 141; 18.1 | 362; 11.7 |
| Hematological diseases (N; %) | 113; 14.5 | 265; 8.6 |
| Hypertension (N; %) | 404; 51.9 | 1119; 36.3 |
| Conduction disorders (N; %) | 92; 11.8 | 338; 11.0 |
| Cardiac dysrhythmias (N; %) | 263; 33.8 | 749; 24.3 |
| Heart failure (N; %) | 279; 35.9 | 590; 19.1 |
| Other cardiac diseases (N; %) | 199; 25.6 | 501; 16.3 |
| Cerebrovascular disease (N; %) | 186; 23.9 | 522; 16.9 |
| Diseases of arteries, arterioles and capillaries (N; %) | 389; 50.0 | 830; 26.9 |
| Chronic obstructive pulmonary disease (N; %) | 146; 18.8 | 334; 10.8 |
| Chronic nephropathies (N; %) | 180; 23.1 | 308; 10.0 |
| Chronic liver, pancreas, digestive diseases (N; %) | 46; 5.9 | 126; 4.1 |
| Gastro-oesophageal haemorrhage (N; %) | 28; 3.6 | 53; 1.7 |
| Evidence-based drug use during the 12 months before admission (at least 2 prescriptions) | ||
| Antiplatelet (N; %) | 269; 34.6 | 802; 26.0 |
| β-Blockers (N; %) | 97; 12.5 | 334; 10.8 |
| ACE-inhibitors/ARBs (N; %) | 374; 48.1 | 1412; 45.8 |
| Statins (N; %) | 126; 16.2 | 350; 11.4 |
ARBs, angiotensin receptor blockers; PCI, percutaneous coronary intervention.